BCM
CRSP icon

Bourgeon Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Bourgeon Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,600
Closed -$266K – 107
2026
Q1 		$266K Buy
+5,600
New +$295K 0.05% 91
2024
Q1 		– Sell
-550
Closed -$34.4K – 158
2023
Q4 		$34.4K Buy
550
+500
+1,000% +$27.6K 0.01% 172
2023
Q3 		$2.27K Hold
50
– – ﹤0.01% 287
2023
Q2 		$2.81K Sell
50
-2,000
-98% -$113K ﹤0.01% 287
2023
Q1 		$92.7K Buy
2,050
+1,550
+310% +$75.3K 0.02% 120
2022
Q4 		$20.3K Hold
500
– – 0.01% 199
2022
Q3 		$33K Hold
500
– – 0.01% 153
2022
Q2 		$30K Sell
500
-1,300
-72% -$76.4K 0.01% 159
2022
Q1 		$113K Buy
1,800
+750
+71% +$47.1K 0.03% 118
2021
Q4 		$80K Buy
1,050
+500
+91% +$43.7K 0.02% 131
2021
Q3 		$62K Buy
+550
New +$69.1K 0.01% 153
2021
Q1 		– Sell
-100
Closed -$15K – 282
2020
Q4 		$15K Buy
+100
New +$11.8K ﹤0.01% 198

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bourgeon Capital Management's CRSP Position: Q2 2026 in Review

Bourgeon Capital Management sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 5,600 shares — an estimated $266K sold.

Bourgeon Capital Management first reported a position in CRSP in Q4 2020 and held it in 12 quarters. The position peaked at $266K in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Bourgeon Capital Management reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bourgeon Capital Management sold 5,600 CRISPR Therapeutics shares in Q2 2026, an estimated $266K.
  • Bourgeon Capital Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 12 quarters.
  • Bourgeon Capital Management's CRISPR Therapeutics position peaked at $266K in Q1 2026.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bourgeon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.